Dow Jones

39,806.77

-0.49%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Hollis-Eden Pharmaceuticals (MM) (HEPH)
Hollis-Eden Pharmaceuticals (MM) (HEPH) Noticias

HEPH

Hollis-Eden Pharmaceuticals (MM) (HEPH)

Hollis-Eden Pharmaceuticals (MM)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HEPH

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/02/2010	15:03	PR Newswire (US)	Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to 'HRBR'	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
16/02/2010	15:27	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
03/02/2010	13:39	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
06/01/2010	15:31	Edgar (US Regulatory)	Securities Registration Statement (simplified form) (S-3/A)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
22/12/2009	15:38	Edgar (US Regulatory)	Securities Registration Statement (simplified form) (S-3)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
15/12/2009	05:03	Edgar (US Regulatory)	Securities Registration (section 12(b)) (8-A12B)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
16/11/2009	08:00	PR Newswire (US)	Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Ta	NASDAQ:HEPH
12/11/2009	15:37	PR Newswire (US)	Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer	NASDAQ:HEPH
06/11/2009	16:23	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
20/10/2009	08:11	PR Newswire (US)	Hollis-Eden Pharmaceuticals Retains Burrill LLC to Provide Exclusive Advisory Services for Lead Programs	NASDAQ:HEPH
16/09/2009	07:30	PR Newswire (US)	Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price	NASDAQ:HEPH
15/06/2009	06:05	PR Newswire (US)	Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
07/05/2009	16:00	Edgar (US Regulatory)	Proxy Statement (definitive) (DEF 14A)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
31/03/2009	16:36	Business Wire	Hollis-Eden Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
31/03/2009	16:28	Edgar (US Regulatory)	Annual Report (10-K)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
20/01/2009	09:54	Edgar (US Regulatory)	Statement of Ownership (SC 13G)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
12/12/2008	16:18	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (S-8)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
17/11/2008	08:28	Business Wire	Richard Hollis, Chairman, President and CEO of Hollis-Eden Pharmaceuticals Talks to The Wall Street Transcript	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
07/11/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Updates Upcoming Investor Conference Presentations and Webcasts	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
06/11/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces Third Quarter 2008 Financial Results	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
15/10/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals to Webcast Investor Conference Presentations and Third Quarter 2008 Conference Call	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
29/09/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE(TM) (HE3235) in Preclinical Models of Castration-	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
25/09/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resi	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
28/08/2008	11:33	Edgar (US Regulatory)	Hollis Eden Pharmaceuticals Inc /DE/ - Confidential Treatment Order (CT ORDER)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
07/08/2008	11:21	Edgar (US Regulatory)	Hollis Eden Pharmaceuticals Inc /DE/ - Current report filing (8-K)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
07/08/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2008 Financial Results	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
07/08/2008	05:05	Edgar (US Regulatory)	Hollis Eden Pharmaceuticals Inc /DE/ - Quarterly Report (10-Q)	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
05/08/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Rheumatoid Arthritis Patients	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
01/08/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Second Quarter 2008 Results and Drug Development Programs	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)
30/07/2008	06:00	Business Wire	Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with APOPTONE(TM) (HE3235) in Late-Stage Prostate Cancer Patient	NASDAQ:HEPH	Hollis-Eden Pharmaceuticals (MM)